Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis
| Autor: | Annelise Hansen, Tacjana Pressler, Birgitte Lidegaard Frederiksen, Niels Høiby, Christian Koch |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Cystic Fibrosis Cystic fibrosis Gastroenterology Pulmonary function testing Lower respiratory tract infection Internal medicine Administration Inhalation medicine Pneumonia Bacterial Deoxyribonuclease I Humans Respiratory system Child Lung business.industry Respiratory disease Infant Dornase alfa General Medicine medicine.disease Anti-Bacterial Agents Pneumonia medicine.anatomical_structure Child Preschool Pediatrics Perinatology and Child Health Immunology Female business medicine.drug |
| Zdroj: | Acta paediatrica (Oslo, Norway : 1992). 95(9) |
| ISSN: | 0803-5253 |
| Popis: | Background: Aerosolized recombinant human deoxyribonuclease (rhDNase I (Pulmozyme®)) has previously been shown to increase pulmonary function and reduce exacerbations of respiratory symptoms in cystic fibrosis (CF) patients with moderate to severe reduction in pulmonary function. Aim: To analyse whether aerosolized Pulmozyme® could reduce the number of bacterial infections in the lower respiratory airways of CF patients without chronic pulmonary infection. Methods: Patients were randomized either to aerosolized Pulmozyme® 2½ mg once daily or to no rhDNase treatment. The study period was 1 y, and the study was blinded for the Department of Clinical Microbiology. Results: Overall, the number of positive cultures was significantly higher in the untreated group (82%) compared with the treated group (72%) (p < 0.05). The most striking difference was found for Staphylococcus aureus, with a prevalence of 30% in the untreated group compared with 16% in the treated group (Χ 2 test, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text